Global SPECT Radiopharmaceuticals Market Size By Type (Technetium99, Thallium-201), By Application (Oncology, Cardiology), By Region, And Segment Forecasts, 2023 to 2032

The Global SPECT Radiopharmaceuticals Market was valued at USD 5.1 billion in 2023 and is projected to reach USD 8.6 billion by 2031, expanding at a CAGR of 6.4% from 2023 to 2031. The market growth is driven by the rising prevalence of cardiovascular diseases and cancers, increased utilization of SPECT (Single Photon Emission Computed Tomography) in diagnostic imaging, and growing adoption of personalized medicine. SPECT radiopharmaceuticals play a crucial role in nuclear imaging procedures by enabling functional visualization of organs and tissues, thereby facilitating early and accurate diagnosis.

Drivers:

1. Rising Burden of Chronic Diseases:

The increasing incidence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is one of the major drivers. SPECT imaging offers valuable insights into disease progression and response to treatment.

2. Technological Advancements in Imaging:

Innovations in SPECT imaging systems and radiopharmaceutical formulations, including hybrid imaging technologies and high-sensitivity detectors, are enhancing diagnostic accuracy and expanding clinical applications.

3. Shift Toward Personalized Medicine:

There is a growing emphasis on precision diagnostics and targeted therapies, where radiopharmaceuticals are used to tailor treatment plans, especially in oncology and cardiology.

Restraints:

1. Short Half-Life of Radiotracers:

Many radiopharmaceuticals have short half-lives, necessitating on-site or nearby production facilities, which limits accessibility and increases logistical challenges.

2. Regulatory and Manufacturing Complexities:

Strict regulations surrounding the production, handling, and transport of radioactive materials, coupled with high manufacturing costs, pose barriers to market entry and scalability.

Opportunity:

1. Growing Adoption in Emerging Markets:

Developing countries are expanding their nuclear medicine infrastructure. Increased healthcare investments and growing awareness present significant opportunities for market expansion.

2. Development of Novel Radiopharmaceuticals:

Ongoing research in theranostics and targeted radiotracers offers new avenues for disease-specific radiopharmaceuticals, driving innovation and market growth.

Market by System Type Insights:

By system type, Technetium-99m-based Radiopharmaceuticals held the largest market share in 2023. Their widespread usage in SPECT imaging for myocardial perfusion, bone scans, and renal diagnostics is attributed to their optimal half-life and cost-effectiveness. Meanwhile, Iodine-based radiopharmaceuticals are gaining momentum in thyroid disorder diagnostics.

Market by End-use Insights:

Hospitals dominated the market in 2023 due to the availability of advanced imaging equipment, skilled professionals, and higher patient footfall. Diagnostic imaging centers are expected to exhibit strong growth over the forecast period, supported by increasing outsourcing of imaging services and cost-efficient infrastructure.

Market by Regional Insights:

North America led the global SPECT radiopharmaceuticals market in 2023, owing to a strong presence of nuclear medicine facilities, favorable reimbursement policies, and high healthcare spending. Asia-Pacific is projected to register the highest CAGR through 2031, fueled by rising disease burden, increasing medical tourism, and significant investments in nuclear imaging infrastructure across India, China, and Southeast Asia.

Competitive Scenario:

Key players in the global SPECT radiopharmaceuticals market include Cardinal Health, GE Healthcare, Curium Pharma, Jubilant Radiopharma, Lantheus Medical Imaging, Siemens Healthineers, Bracco Imaging, NorthStar Medical Radioisotopes, Nihon Medi-Physics, and Advanced Accelerator Applications (Novartis Group). These companies focus on expanding production capabilities, acquiring specialized radiopharma firms, and collaborating with healthcare institutions.

Recent Developments:

In 2023, GE Healthcare introduced a next-gen SPECT/CT system integrated with AI algorithms to enhance image quality and reduce scan times.

Curium Pharma received FDA approval in 2024 for its novel technetium-labeled cardiac imaging agent.

Jubilant Radiopharma expanded its cyclotron network in 2025 to support wider regional access to SPECT diagnostics across North America.

Scope of Work – Global SPECT Radiopharmaceuticals Market

Key Market Developments:

2023: GE Healthcare launched advanced AI-integrated SPECT/CT systems to improve diagnostic efficiency.

2024: Curium Pharma gained regulatory clearance for a new cardiac-specific radiotracer.

2025: NorthStar Medical Radioisotopes partnered with a leading U.S. hospital chain to supply next-gen SPECT isotopes.

FAQs:

1) What is the current market size of the Global SPECT Radiopharmaceuticals Market?

The market was valued at USD 5.1 billion in 2023.

2) What is the major growth driver of the Global SPECT Radiopharmaceuticals Market?

The primary growth driver is the rising prevalence of chronic diseases and the increasing demand for accurate and early diagnostics.

3) Which is the largest region during the forecast period in the Global SPECT Radiopharmaceuticals Market?

North America held the largest share in 2023, but Asia-Pacific is expected to grow at the fastest rate.

4) Which segment accounted for the largest market share in the Global SPECT Radiopharmaceuticals Market?

Technetium-99m-based radiopharmaceuticals led the market in 2023.

5) Who are the key market players in the Global SPECT Radiopharmaceuticals Market?

Major players include Cardinal Health, GE Healthcare, Curium Pharma, Jubilant Radiopharma, and Siemens Healthineers.